Published inAmplitude VCThe Path to Exit: How Celsius Therapeutics got acquired by AbbVieThe story behind how Celsius Therapeutics was acquired by AbbvieDec 18, 2024Dec 18, 2024
Published inAmplitude VCThe Pre-Amp Fellowship in 2024Cultivating the next generation of leaders in precision medicineDec 18, 2024Dec 18, 2024
Published inAmplitude VCFluid Biomed’s Series A — Advancing Novel Treatments for Brain AneurysmsFluid Biomed’s $27M US oversubscribed Series A financing.Dec 16, 2024Dec 16, 2024
Published inAmplitude VCEvommune’s Series C — Advancing New Therapies in Chronic Inflammatory DiseasesEvommune’s $115M Series COct 31, 2024Oct 31, 2024
Published inAmplitude VCNomic Bio’s Series B — Making proteomics accessibleNomic’s $42M Oversubscribed Series B FinancingSep 17, 2024Sep 17, 2024
Published inAmplitude VCRadiant Biotherapeutics Series A — Bringing Multabodies to PatientsAnnouncement of Radiant’s $35M Series ASep 11, 2024Sep 11, 2024
Published inAmplitude VCA New Chapter in Precision Medicine: Announcing Amplitude’s Second FundCelebrating the closing of our second fundMay 28, 2024May 28, 2024
Published inAmplitude VCReverb Therapeutics — Redirecting endogenous cytokinesLaunching Reverb Therapeutics out of stealth mode to redirect endogenous cytokines using antibodiesNov 15, 2023Nov 15, 2023
Published inAmplitude VCTentarix — creating next-generation multi-functional biologicsAnnouncing our lead investment into a $35M Series B financing of antibody developer TentarixSep 6, 2023Sep 6, 2023
